Could a daily injection help kids with rare bone diseases grow taller?
NCT ID NCT05845749
First seen Mar 20, 2026 · Last updated May 07, 2026 · Updated 5 times
Summary
This early-phase study tests whether vosoritide, a daily injection, can safely improve growth in children with MPS IVA or VI, two rare genetic disorders that cause short stature and bone problems. Six children aged 5 to 10 will receive the drug for 96 weeks, with researchers monitoring side effects and changes in height. The goal is to see if the treatment is safe and may help these children grow more than they would without it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MPS IVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSF Benioff Children's Hospital Oakland
Oakland, California, 94609, United States
Conditions
Explore the condition pages connected to this study.